Akari Therapeutics (AKTX): CFO received 1,284 shares
Kameel D. Farag, CFO at Akari Therapeutics, reported a grant / award of 1,284 shares.
- 1,284
- Shares · @ $10.12
- Traded
- Nov 17, 2026
- Filed
- Nov 19, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Sep 29, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On September 29, 2026, Akari Therapeutics, Plc (the “ Company ”), entered into an amendment (the “ CEO Agreement Amendment ”), to its Chief Executive Officer Agreement, dated as of March 14, 2025, with Abizer Gaslightwala, the Company’s Chief Executive Officer (the “ CEO Agreement ”), which amended the CEO Agreement to provide for the following: ● an increase in Mr. Gaslightwala’s annual base salary from $475,000 to…”
- Nov 12, 2026Company filing · Form 8-K · ResultsReported its results
- Nov 12, 20265% stakeBank of Montreal reported a passive stake (13G) of 0.8%
- Nov 13, 20265% stakeMMCAP International Inc. SPC reported a passive stake (13G) of 0.6%
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Akari Therapeutics
For Akari Therapeutics, OQRO holds 2 fund holdings reports (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its AKTX page.
How this filing works
Explore the data
Common questions
Which Akari Therapeutics (AKTX) insider traded, and how much?
Kameel D. Farag, CFO at Akari Therapeutics, reported a grant / award of 1,284 shares. At $10.12.
When did it happen, and when was it made public?
Traded: Nov 17, 2026. Filed: Nov 19, 2026. That is 2 days between the two dates.
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Akari Therapeutics recently?
For Akari Therapeutics, OQRO holds 2 fund holdings reports (13F) dated in the last 90 days. They are listed on the AKTX page.
Does this mean AKTX stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Akari Therapeutics
- SEC Schedule 13GNov 13, 2026
- SEC Schedule 13GNov 12, 2026
- SEC Form 4Aug 29, 2025
- SEC Form 4Aug 29, 2025
- SEC Form 4Aug 29, 2025
- SEC Form 4Jun 25, 2025
Everything OQRO holds on this company is on its AKTX page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
